Extramitral Valvular Cardiac Involvement in Patients With Significant Secondary Mitral Regurgitation.

Autor: Singh GK; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands., Namazi F; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands., Hirasawa K; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands., van der Bijl P; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands., van Wijngaarden AL; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands., Vo NM; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands., Stone GW; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; The Cardiovascular Research Foundation, New York, New York., Ajmone Marsan N; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands., Delgado V; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands., Bax JJ; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; Turku Heart Center, University of Turku and Turku University Hospital, Turku, Finland. Electronic address: j.j.bax@lumc.nl.
Jazyk: angličtina
Zdroj: The American journal of cardiology [Am J Cardiol] 2022 Jan 01; Vol. 162, pp. 143-149. Date of Electronic Publication: 2021 Oct 24.
DOI: 10.1016/j.amjcard.2021.09.022
Abstrakt: Patients with secondary mitral regurgitation (SMR) often have extramitral valve cardiac involvement, which can influence the prognosis. SMR can be defined according to groups of extramitral valve cardiac involvement. The prognostic implications of such groups in patients with moderate and severe SMR (significant SMR) are unknown. A total of 325 patients with significant SMR were classified according to the extent of cardiac involvement on echocardiography: left ventricular involvement (group 1), left atrial involvement (group 2), tricuspid valve and pulmonary artery vasculature involvement (group 3), or right ventricular involvement (group 4). The primary end point was all-cause mortality. The prevalence of each cardiac involvement group was 17% in group 1, 12% in group 2, 23% in group 3%, and 48% in group 4. Group 3 and group 4 were independently associated with all-cause mortality (hazard ratio 1.794, 95% confidence interval 1.067 to 3.015, p = 0.027 and hazard ratio 1.857, 95% confidence interval 1.145 to 3.012, p = 0.012, respectively). In conclusion, progressive extramitral valve cardiac involvement (group 3 and group 4) was independently associated with all-cause mortality in patients with significant SMR.
Competing Interests: Disclosures The Department of Cardiology of the Leiden University Medical Center received research grants from Abbott Vascular, Bayer, Bioventrix, Biotronik, Boston Scientific, Edwards Lifesciences, GE Healthcare, and Medtronic. Victoria Delgado received speaker fees from Abbott Vascular, Edward Lifesciences, GE Healthcare, Merck Sharp & Dohme, and Medtronic. Nina Ajmone Marsan received speakers fees from Abbott Vascular and GE Healthcare. Jeroen J Bax received speaker fees from Abbott Vascular. The remaining authors have no conflicts of interest to declare.
(Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: